Precision Oncology Platform Turning Point Therapeutics, in partnership with Bristol Myers Squibb, is advancing a precision oncology platform for cancer patients, presenting a sales opportunity for pharmaceutical products targeting specific genetic mutations.
New Medication Launch Bristol-Myers Squibb's recent launch of Cobenfy, a new medication combining xanomeline and trospium chloride, opens avenues for sales representatives to promote this innovative treatment in the pharmaceutical market.
Client Acquisition Securing Opdivo as a client for Bristol-Myers Squibb positions sales teams to capitalize on promoting the only FDA-approved PD-1 inhibitor for specific types of lung cancer, presenting sales opportunities in oncology and immunotherapy markets.
Strategic Partnership with University The collaboration between the University of Texas at San Antonio and Bristol-Myers Squibb to advance pharmaceutical discoveries creates opportunities for sales development representatives to leverage academic-industry partnerships in selling innovative healthcare solutions.
Prime Edited T-Cell Therapies Bristol-Myers Squibb's development of Prime edited ex vivo T-cell therapies through a strategic collaboration with Prime Medicine opens sales avenues for representatives to explore cutting-edge cell therapy treatments in the biotechnology research sector.
501
$50M$100M
66
966$100M$1B
160$10M$50M
146$10M$50M
413$50M$100M
114$10M$50M
11
731$100M$1BTurning Point Therapeutics uses 8 technology products and services including Microsoft SQL Server Management Studio, Microsoft Word, DMARC, and more. Explore Turning Point Therapeutics's tech stack below.
| Turning Point Therapeutics Email Formats | Percentage |
| First.Last@tptherapeutics.com | 95% |
| Last@tptherapeutics.com | 4% |
| F_Last@tptherapeutics.com | 1% |
| First.Last@bms.com | 94% |
| LastF@bms.com | 3% |
| Last.First@bms.com | 2% |
| First.Middle@bms.com | 1% |
Biotechnology ResearchCalifornia, United States201-500 Employees
We officially combined with Bristol Myers Squibb to advance our precision oncology platform for patients. Visit www.bms.com to learn more about our work to produce the next generation of medicines for cancer patients. For more information on the acquisition, read our press release at: bit.ly/3Uccbu8
Company Overview
Media & News
Funding & FinancialsTurning Point Therapeutics has raised a total of $460M of funding over 8 rounds. Their latest funding round was raised on Oct 26, 2020 in the amount of $460M.
Turning Point Therapeutics's revenue is in the range of $50M$100M
Funding & FinancialsTurning Point Therapeutics has raised a total of $460M of funding over 8 rounds. Their latest funding round was raised on Oct 26, 2020 in the amount of $460M.
Turning Point Therapeutics's revenue is in the range of $50M$100M
1-888-653-2347 
support@leadiq.com